Detalles de la búsqueda
1.
Hepatocellular Carcinoma Risk Scores Predict Patients Under Surveillance at Low Risk of Benefit and High Risk of Harm.
Dig Dis Sci
; 68(3): 770-777, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36376575
2.
Comparing Predicted Probability of Hepatocellular Carcinoma in Patients With Cirrhosis With the General Population: An Opportunity to Improve Risk Communication?
Am J Gastroenterol
; 117(9): 1454-1461, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35973177
3.
Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon-free therapies: A population-based cohort study.
Liver Int
; 42(3): 561-574, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34951109
4.
Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
J Viral Hepat
; 28(9): 1246-1255, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34002914
5.
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
J Viral Hepat
; 28(11): 1635-1642, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34448313
6.
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
J Hepatol
; 73(6): 1368-1378, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32707225
7.
Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype.
J Viral Hepat
; 27(10): 996-1002, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32479681
8.
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
J Viral Hepat
; 27(4): 371-375, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31756019
9.
Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
J Viral Hepat
; 27(3): 270-280, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31696575
10.
The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen.
J Hepatol
; 68(4): 646-654, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29155019
11.
Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.
J Hepatol
; 66(1): 19-27, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27545496
12.
Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
J Virol
; 90(9): 4530-4543, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26912610
13.
Factors associated with spontaneous clearance of chronic hepatitis C virus infection.
J Hepatol
; 65(2): 266-72, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27155531
14.
Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
Hepatology
; 62(2): 355-64, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25716707
15.
The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut.
J Hepatol
; 72(5): 1034-1035, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31836548
16.
Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection.
Liver Int
; 35(10): 2256-64, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25800823
17.
Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model.
J Hepatol
; 60(6): 1118-26, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24509410
18.
Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus.
PLoS One
; 18(1): e0280551, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36689413
19.
Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.
BMJ
; 382: e074001, 2023 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37532284
20.
Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment.
Viruses
; 14(8)2022 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36016300